世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

会員登録

マイページ

中東の医療機器市場:製品別[体外診断(IVD)、心臓病、整形外科]、FDAクラス分類別(クラスI、II、III)、エンドユーザ別、地域別分析とセグメント予測 2014-2025年

Middle East Medical Device Market By Product (In Vitro Diagnostics (IVD), Cardiology, Orthopedics), By FDA classification (Class I, II, III), By End-user, By Region, And Segment Forecasts, 2014 - 2025

 

出版社 出版年月電子媒体価格ページ数
Grand View Research
グランドビューリサーチ
2017年10月US$4,950
シングルユーザライセンス
165

サマリー

この調査レポートは中東の医療機器市場を分析・予測したGrand View Researchの市場調査報告書です。

Description

The Middle East medical devices market is expected to reach USD 31.6 billion by 2025, according to a new report by Grand View Research, Inc. This growth is anticipated to be a result of increasing geriatric population, and increasing incidences of conventional diseases such as diabetes and obesity. Other major drivers include technological innovations and increasing demand and acceptance of such technologies in Middle Eastern countries majorly in UAE, Saudi Arabia and Qatar.

Furthermore, rising competitive pressure is witnessed in the Middle East medical device market as a result of high demand and low supply ratio. Hence, it can be predicted that the Middle East medical device market may witness lucrative growth over the forecast period.

Another factor responsible for this propelling growth is the supportive reimbursement pathways adapted by the Middle Eastern countries majorly to ensure quality healthcare provisions for every civilian. Major developments are witnessed in terms of regulatory structures as well, with an agenda to provide monetary benefits to the civilians and improve overall lifestyle of the people.

Further Key Findings From The Study Suggest:

-Based on product type, In-Vitro Diagnostics(IVD) is expected to dominate the market as of 2016. Furthermore, neurology device segment is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence of conventional diseases, augmenting research and technological advancement offered by key industry players to meet the current unmet needs.

-The medical devices are also analyzed depending upon the U.S. FDA classification, with Class II being the dominant as well as the fastest growing segment during the forecast period. The Class II device segment is anticipated to capture over 60.0% of the market share by 2025.

-Geographic expansion into Qatar, U.A.E. and Iraq by well-established players is anticipated to promote the fastest growth for the region.

-Few of the industry players for the Middle East medical devices market include Medtronic, Johnson & Johnson, Siemens, Roche, Becton Dickinson and Abbott Laboratories

-Entry of various new players coupled with collaborative efforts by existing players is expected to be witnessed over the forecast period.

-For instance, In December 2016, Becton Dickinson announced a research collaboration with a leading global organization the Juvenile Diabetes Research Foundation(JDRF) that would be funding their research for type 1 diabetes. This is anticipated to enable BD’s focus on enhancing technology supporting extended wear insulin infusion set.



目次

Table of Content

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.1.1. Purchased Database
1.1.2. GVR’s Internal Database
1.2. Data Analysis
1.3. Market Formulation & Validation
1.4. Approaches for Market Estimation
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Middle East Medical Device Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Size & Growth Prospects
3.3. Market Driver Analysis
3.4. Market Restraint Analysis
3.5. Penetration & Growth Prospect Mapping
3.6. SWOT Analysis, By Factor
3.6.1. Political
3.6.2. Economic
3.6.3. Technological
3.7. Industry Analysis - Porter’s
3.8. Middle East medical devices market: Regulation Analysis
3.9. Reimbursement Pathways
Chapter 4. Middle East Medical Device Market: Product Estimates & Trend Analysis
4.1. Product Movement Analysis & Market Share, 2016 & 2025
4.2. Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following products:
4.2.1. Types of Devices
4.2.1.1. In Vitro Diagnostics (IVD)
4.2.1.2. Cardiology
4.2.1.3. Orthopedics
4.2.1.4. Diagnostic imaging
4.2.1.5. Ophthalmic
4.2.1.6. General and plastic surgery
4.2.1.7. Drug delivery
4.2.1.8. Endoscopy
4.2.1.9. Dental
4.2.1.10. Wound management
4.2.1.11. Diabetic care
4.2.1.12. Nephrology
4.2.1.13. Ear, Nose and Throat
4.2.1.14. General hospital and Healthcare
4.2.1.15. Neurology
4.2.1.16. Skin Care & Aesthetics
4.2.1.17. Others
Chapter 5. Middle East Medical Device Market: FDA Classification Estimates & Trend Analysis
5.1. FDA Classification Movement Analysis & Market Share, 2016 & 2025
5.2. Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following classes:
5.2.1. Class I
5.2.2. Class II
5.2.3. Class III
Chapter 6. Middle East Medical Device Market: End-use Estimates & Trend Analysis
6.1 End-use Movement Analysis & Market Share, 2016 & 2025
6.2 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following end-use:
6.2.1 Hospital
6.2.2 Clinics
6.2.3 Laboratories
6.2.4 Blood Banks
6.2.5 Pharmacies
6.2.6 Stand-alone Clinics
6.2.7 Dermatology Clinics & Cosmetic Centers
6.2.8 Others
Chapter 7. Middle East Medical Device Market: Regional Estimates & Trend Analysis
7.1. Regional Movement Analysis & Market Share, 2016 & 2025
7.2. Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following regions:
7.2.1. Saudi Arabia
7.2.1.1. Saudi Arabia market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.1.2. Saudi Arabia market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.1.3. Saudi Arabia market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.2. UAE
7.2.2.1. UAE market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.2.2. UAE market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.2.3. UAE market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.3. Qatar
7.2.3.1. Qatar market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.3.2. Qatar market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.3.3. Qatar market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.4. Kuwait
7.2.4.1. Kuwait market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.4.2. Kuwait market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.4.3. Kuwait market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.5. Oman
7.2.5.1. Oman market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.5.2. Oman market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.5.3. Oman market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.6. Bahrain
7.2.6.1. Bahrain market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.6.2. Bahrain market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.6.3. Bahrain market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.7. Egypt
7.2.7.1. Egypt market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.7.2. Egypt market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.7.3. Egypt market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.8. Iran
7.2.8.1. Iran market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.8.2. Iran market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.8.3. Iran market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.9. Iraq
7.2.9.1. Iraq market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.9.2. Iraq market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.9.3. Iraq market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.10. Israel
7.2.10.1. Israel market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.10.2. Israel market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.10.3. Israel market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.11. Cyprus
7.2.11.1. Cyprus market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.11.2. Cyprus market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.11.3. Cyprus market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.12. Jordan
7.2.12.1. Jordan market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.12.2. Jordan market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.12.3. Jordan market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.13. Turkey
7.2.13.1. Turkey market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.13.2. Turkey market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.13.3. Turkey market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.14. Lebanon
7.2.14.1. Lebanon market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.14.2. Lebanon market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.14.3. Lebanon market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
7.2.15. Palestine
7.2.15.1. Palestine market estimates and forecasts, by product, 2014 - 2025 (USD Million)
7.2.15.2. Palestine market estimates and forecasts, by FDA classification, 2014 - 2025 (USD Million)
7.2.15.3. Palestine market estimates and forecasts, by end-use, 2014 - 2025 (USD Million)
Chapter 8. Competitive Landscape
8.1. Strategic Recommendation
8.2. Strategy Framework
8.2.1. Company Profiles
8.2.2. Medtronic
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Geographic Foothold
8.2.2.4. Product Benchmarking
8.2.2.5. Strategic Initiatives
8.2.3. Johnson & Johnson
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Geographic Foothold
8.2.3.4. Product Benchmarking
8.2.3.5. Strategic Initiatives
8.2.4. Siemens
8.2.4.1. Company Overview
8.2.4.2. Financial Performance
8.2.4.3. Product Benchmarking
8.2.4.4. Strategic Initiatives
8.2.5. Roche
8.2.5.1. Company Overview
8.2.5.2. Financial Performance
8.2.5.3. Product Benchmarking
8.2.5.4. Strategic Initiatives
8.2.6. Becton Dickinson
8.2.6.1. Company Overview
8.2.6.2. Financial Performance
8.2.6.3. Product Benchmarking
8.2.6.4. Strategic Initiatives
8.2.7. Abbott Laboratories
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Product Benchmarking
8.2.7.4. Strategic Initiatives
8.2.8. Novartis
8.2.8.1. Company Overview
8.2.8.2. Financial Performance
8.2.8.3. Product Benchmarking
8.2.8.4. Strategic Initiatives
8.2.9. Olympus Corporation
8.2.9.1. Company Overview
8.2.9.2. Financial Performance
8.2.9.3. Product Benchmarking
8.2.9.4. Strategic Initiatives
8.2.10. General Electric
8.2.10.1. Company Overview
8.2.10.2. Financial Performance
8.2.10.3. Product Benchmarking
8.2.10.4. Strategic Initiatives
8.2.11. Biomerica
8.2.11.1. Company Overview
8.2.11.2. Financial Performance
8.2.11.3. Product Benchmarking
8.2.11.4. Strategic Initiatives
8.2.12. Baxter International
8.2.12.1. Company Overview
8.2.12.2. Financial Performance
8.2.12.3. Product Benchmarking
8.2.12.4. Strategic Initiatives
8.2.13. Smith and Nephew
8.2.13.1. Company Overview
8.2.13.2. Financial Performance
8.2.13.3. Product Benchmarking
8.2.13.4. Strategic Initiatives
8.2.14. BioM?rieux
8.2.14.1. Company Overview
8.2.14.2. Financial Performance
8.2.14.3. Product Benchmarking
8.2.14.4. Strategic Initiatives
8.2.15. Philips
8.2.15.1. Company Overview
8.2.15.2. Financial Performance
8.2.15.3. Product Benchmarking
8.2.15.4. Strategic Initiatives
8.2.16. Zimmer Biomet
8.2.16.1. Company Overview
8.2.16.2. Financial Performance
8.2.16.3. Product Benchmarking
8.2.16.4. Strategic Initiatives





 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問い合せは、お電話・メール・WEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問い合せはこちらのフォームから承ります

office@dri.co.jp

 

ページTOPに戻る